Successful Development of Cancer Immunization Innovative Treatment Using Salmonella
Aug 13, 2024
A research team led by Professor Min Jeong-joon of Hwasun Chonnam National University Hospital, who is leading the development of new cancer immunotherapy using bacteria, is drawing attention.
In particular, related research papers have recently been published one after another in Nature, the best international journal for oncology, and have been recognized for their world-class research ability.
A research team led by Min Jeong-joon, a professor of nuclear medicine at Hwasun Chonnam National University Hospital, and Hong Young-jin, a professor at Chonnam National University of Medicine, recently succeeded in developing a new concept of immunotherapy that can reprogram the tumor microenvironment by producing bacteria for cancer treatment that are genetically fused by salmonella, E. coli, and vibrio.
The research paper 'Reprogramming the tumor immune microenvironment using engineered salmonella equipped with double drugs (engineered dual-drug loaded Salmonella)' was introduced in the August 6 issue of Nature Communications. Professor Min Jeong-jun's research team was carried out with the support of the Ministry of Science and ICT's Immunotherapy Innovation Platform Project and the mid-sized research project.
Salmonella has a strong affinity for cancer tissues, so when injected into the body, it grows about 100,000 times more in cancer tissues than in normal tissues.
Professor Min Jeong-joon's research team genetically designed Salmonella strains, whose toxicity has been greatly weakened, to produce cytolysin A (cytolysin A), a cytolytic protein of E. coli, and flagellin B (flagellin B), a flagellum of Vibrio bacteria, in cancer tissues.
As a result of testing this fusion Salmonella on a mouse model implanted with various types of cancer, it was found that it can effectively treat primary cancer as well as metastatic cancer by dramatically changing the cancer immune microenvironment.
Professor Min Jeong-jun "While research on developing bacteria such as Salmonella as cancer treatments is underway around the world, we are leading the technology to produce various genetically engineered Salmonella and use it for targeted cancer treatment."It is expected to be a new paradigm of innovative immunotherapy that causes strong immune action." he said.
Prior to this, Professor Min Jeong-jun announced a study on the status of developing bacteria as cancer immunotherapy in June with Professor Kwon Sung-young of the Department of Nuclear Medicine and Professor Hong Young-jin of Chonnam Medical University. This research paper was also published in the world's top journal 'Nature Review Clinical Oncology', with the Impact Factor, an indicator of influence, reaching 81.1.
In particular, related research papers have recently been published one after another in Nature, the best international journal for oncology, and have been recognized for their world-class research ability.
A research team led by Min Jeong-joon, a professor of nuclear medicine at Hwasun Chonnam National University Hospital, and Hong Young-jin, a professor at Chonnam National University of Medicine, recently succeeded in developing a new concept of immunotherapy that can reprogram the tumor microenvironment by producing bacteria for cancer treatment that are genetically fused by salmonella, E. coli, and vibrio.
The research paper 'Reprogramming the tumor immune microenvironment using engineered salmonella equipped with double drugs (engineered dual-drug loaded Salmonella)' was introduced in the August 6 issue of Nature Communications. Professor Min Jeong-jun's research team was carried out with the support of the Ministry of Science and ICT's Immunotherapy Innovation Platform Project and the mid-sized research project.
Salmonella has a strong affinity for cancer tissues, so when injected into the body, it grows about 100,000 times more in cancer tissues than in normal tissues.
Professor Min Jeong-joon's research team genetically designed Salmonella strains, whose toxicity has been greatly weakened, to produce cytolysin A (cytolysin A), a cytolytic protein of E. coli, and flagellin B (flagellin B), a flagellum of Vibrio bacteria, in cancer tissues.
As a result of testing this fusion Salmonella on a mouse model implanted with various types of cancer, it was found that it can effectively treat primary cancer as well as metastatic cancer by dramatically changing the cancer immune microenvironment.
Professor Min Jeong-jun "While research on developing bacteria such as Salmonella as cancer treatments is underway around the world, we are leading the technology to produce various genetically engineered Salmonella and use it for targeted cancer treatment."It is expected to be a new paradigm of innovative immunotherapy that causes strong immune action." he said.
Prior to this, Professor Min Jeong-jun announced a study on the status of developing bacteria as cancer immunotherapy in June with Professor Kwon Sung-young of the Department of Nuclear Medicine and Professor Hong Young-jin of Chonnam Medical University. This research paper was also published in the world's top journal 'Nature Review Clinical Oncology', with the Impact Factor, an indicator of influence, reaching 81.1.
|
bellho@sportschosun.com
